The clinical pharmacology of the new reversible monoamine oxidase (MAO) inhibitor, moclobemide, was examined in three separate studies in healthy male volunteers. In a single oral dose study, moclobemide (25-150 mg) was rapidly absorbed from the gastrointestinal tract and had a relatively short plasma half-life (mean 1.3 h after 150 mg). A decrease in the plasma concentrations of the noradrenaline metabolite 4- hydroxy-3-methoxyphenylglycol (HMPG), however, indicated a longer time to peak pharmacodynamic effect and longer duration of activity. Assay of platelet MAO activity did not reveal any evidence of irreversible inhibition of the B form of the isoenzyme. Single oral doses of moclobemide (150 and 300 mg) significantly lowered the threshold to the cardiovascular effects ('cheese reaction') of intravenous tyramine. However, after repeated administration of 100 mg three times daily for over 2 weeks, moclobemide caused significantly less potentiation than did phenelzine (15 mg three times per day) on the cardiovascular effects of oral tyramine, a clinically more relevant model. The MAO-B inhibitor, selegiline (5 mg once daily), also lowered the oral tyramine threshold significantly. Moclobemide was generally well tolerated by these healthy volunteers.
Get full access to this article
View all access options for this article.
References
1.
Amrein R., Allen S.R., Vranesic D., Stabl M. (1988) Antidepressant drug therapy: associated risks. J Neural Transmission26: (Suppl) 73-86
2.
Asatoor A.M., Levi A.J., Milne M.D. (1963) Tranylcypromine and cheese. Lancetii: 733-734
3.
Baldessarini R.J. (1985) Drugs and the treatment of psychiatric disorders . In Goodman Gilman A, Goodman G S, Rall T W, Maurad F, (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan , New York, pp. 387-445
4.
Bianchine J.R. (1985) Drugs for Parkinson's disease, spasticity and acute muscle spasms. In Goodman Gilman A, Goodman G S, Rall T W, Maurad F, (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan , New York, pp. 473-490
5.
Bieck P.R., Antonin K.H. (1988) Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. Psychopharmacology96(Suppl): 31
6.
Biziere K., Bougault I., Kap J.P., Maouget-Goniot C., Mons G., Worms P. (1985) Effect of two amino-pyridazine derivatives on both forms of monoamine oxidase in rat brain. Br J Pharmacol86: 417P
7.
Caramona M.M., Araújo D., Brandáo F. (1985) Influence of MAO-A and MAO-B on the inactivation of noradrenaline in the saphenous vein of the dog. Naunyn-Schmiedebergs' Arch Pharmacol328: 401-406
8.
Da Prada M., Kettler R., Keller H.H. (1986) Profile neurochimique de l'antidepresseur moclobemide: un nouvel inhibitor reversible de la monoamine oxydase de type A. Co Re CongPsychiat Neurol Franc. LXXXIV session: 329-337
9.
Da Prada M., Keller H.H., Kettler R., Schaffner R., Pieri M., Burkard W.P., Korn A., Haefely W.E. (1982) Ro 11-1163, a specific and short-acting MAO inhibitor with antidepressant properties. In Kamijo K, Usdin E and Nagatsu T (eds), Monoamine oxidase. Basic and clinical frontiers. Excerpta Medica, Amsterdam , pp. 183-196
10.
Da Prada M., Kettler R., Keller H.H., Haefely W.E. (1983) Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor. Modern Problems Pharmacopsychiat19: 231-245
11.
Da Prada M., Kettler R., Burkard W.P., Haefely W.E. (1984) Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats . In Tipton K F, Dostert P, Strolin Benedetti M (eds), Monoamine oxidase and disease; prospects for therapy with reversible inhibitors. Academic Press, London , pp. 137-155
12.
Da Prada M., Zürcher G., Wüthrich I., Haefely W.E. (1988) On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transmission26: (Suppl.) 33-56
13.
Eggers H., Gieschke R., Korner J. (1987) Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by HPLC. J Chromatogr Biomed Appl420: 111-120
14.
Elsworth J.D., Glover V., Reynolds G.P., Sandler M., Lees A.J., Phnapradit P., Shaw K.M., Stern G.M., Kumar P. (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology57: 33-38
15.
Fellows L., Riederer P., Sandler M. (1975) A rapid assay of 4-hydroxy-3-methoxyphenylglycol in urine. Clin Chim Acta59: 255-257
16.
Finberg J P M, Youdim M B H (1984) Reversible monoamine oxidase inhibitors and the cheese effect. In Tipton K F, Dostert P, Strolin Benedetti M (eds), Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp. 479-485
17.
Finberg J P M, Youdim M B H (1988) Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transmission (Suppl.) 26: 11-17
18.
Finberg J P M, Tenne M., Youdim M B H (1981) Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In Youdim M B H, Paykel E S (eds), Monoamine oxidase inhibition—the state of the art. John Wiley, Chichester , pp. 31-43
19.
Giller E., Lieb J. ( 1980) MAO inhibitors and platelet MAO inhibitor. Commun Psychopharmacol4: 79-82
20.
Hannah P., Glover V., Sandler M. (1988) Tyramine in wine and beer. Lanceti : 879
21.
Keller H.H., Kettler R., Keller G., Da Prada M. (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn-Schmiedeberg's Arch Pharmacol335: 12-20
22.
Korn A., Gasic S., Jung M., Eichler H.G., Raffesberg W. (1984) Influence of moclobemide (Ro 11-1163) on the peripheral adrenergic system: interaction with tyramine and tricyclic antidepressants . In Tipton K F, Dostert P, Strolin Benedetti M (eds), Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London , pp. 487-497
23.
Korn A., Eichler H.G., Fischbach R., Gasic S. (1986) Moclobemide, a new reversible MAO inhibitor—interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology88: 153-157
24.
Korn A., Da Prada M., Raffesberg W., Allen S., Gasic S. (1988a) Tyramine pressor effect in man: studies with moclobemide, a novel reversible monoamine oxidase inhibitor. J Neural Transmission (Suppl.) 26: 57-71
25.
Korn A., Da Prada M., Raffesberg W., Gasic S., Eichler H.G. (1988b) Effects of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol11: 17-23
26.
Knoll J. (1981) The pharmacology of selective MAO inhibitors. In Youdim M B H, Paykel E S (eds), Monoamine oxidase inhibitors—the state of the art. John Wiley, Chichester , pp. 45-61
27.
Maas J.W. (1983) Basic mechanisms and psychopathology. Academic Press, New York
28.
Marley E., Blackwell B. (1970) Interaction of monoamine oxidase inhibitors, amines and foodstuffs. Adv Pharmacol Chemother8: 185-239
29.
McCabe B., Tsuang M.T. (1982) Dietary consideration in MAO inhibitor regimens . J Clin Psychiat43: 178-181McCarry W.J., Callingham B.A., Mazel P. (1987) Some in vitro effects of moclobemide on the anococcygeus muscle of the rat . Pharmacol Toxicol60(Suppl 1): 34
30.
Mendis N., Pare C M B, Sandler M., Glover V. and Stern G. (1981) (-)-Deprenyl in the treatment of depression. In Youdim M B H and Paykel E S (eds), Monoamine oxidase inhibitors—the state of the art. John Wiley, Chichester , pp. 171-176
31.
Molyneux S.G., Franklin M. (1985) Routine determination of unconjugated 3-methoxy-4-hydroxyphenylglycol in plasma using high performance liquid chromatography with electrochemical detection. J Chromatogr Biomed Appl341: 160-166
Nies A. ( 1983) Clinical applications of MAOIs. In Burrows G D, Norman T R, Davies B (eds), Drugs in psychiatry, vol 1. Elsevier, Amsterdam, pp. 229-247
34.
Pace D.G., Reele S.B., Rozik L.M., Rogers-Phillips C.A., Dabice J.A., Givens J.V. (1988) Evaluation of methods of administering tyramine to raise systolic blood pressure. Clin Pharmacol Ther44: 137-144
35.
Pare C M B (1985) The present status of monoamine oxidase inhibits . Br J Psychiat146: 576-584
36.
Quitkin F.M. (1985) The importance of dosage in prescribing antidepressants . Br J Psychiat147: 593-597
37.
Reynolds E F (ed.) (1982) Martindale. The extra pharmacopoeia, 28th edn. Pharmaceutical Press, London
38.
Sandler M. (1981) Deprenyl, monoamine oxidase inhibitor and the 'cheese effect': some outstanding problems. In Youdim M B H, Paykel E S (eds), Monoamine oxidase inhibitors—the state of the art. John Wiley, Chichester, pp. 207-212
39.
Sandler M., Reveley M.A., Glover V. (1981) Human platelet monoamine oxidase activity in health and disease: a review. J Clin Pathol34: 292-302
40.
Scheinin M., Koulu M., Zimmer R., Kaartinen A., Kallio J., Pyykkö K. (1988) Plasma dihydroxyphenylglycol (DHPG) reflects MAO-A inhibition by moclobemide in man. Psychopharmacology96(Suppl): 228
41.
Schläppi B. (1985) The lack of hepatotoxicity in the rat with the new and reversible short-acting MAO-A inhibitor moclobemide—in contrast to iproniazid. Arzneim Forsch Drug Res35: 800-803
42.
Schoerlin M.P., Mayersohn M., Korn A., Eggers H. (1987) Disposition kinetics of moclobemide, a MAO-A inhibitor: single and multiple design in normal subjects. Clin Pharmacol Ther42: 395-404
43.
Schoerlin M.P., Mayersohn M., Hoevels B., Eggers H., Dellenbach M., Pfefen J-P. (1988) Effect of food intake on the relative bioavailability of moclobemide (Ro 11-1163). J Neural Transmission26: (Suppl.) 115-121
44.
Simpson G.M., White K. (1984) Tyramine studies and the safety of MAOI drugs. J Clin Psychiat45: 59-61
45.
Stabl M., Biziere K., Schmid-Burg K.W., Amrein R. (1989) Review of comparative trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transmission28: (Suppl) 77-89
46.
Strolin Benedetti M., Boucher T., Carlsson A., Fowler C.J. (1983) Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem Pharmacol32: 47-52
47.
Summers K.M., Brown G.K., Craig I.W., Littlewood J., Peatfield R., Glover V., Rose F.C., Sandler M. (1982) Platelet monoamine oxidase: specific activity and turnover number in headache. Clin Chem Acta121: 139-146
Tipton K.F., Dostert P., Strolin Benedetti M. (1984) Monoamine oxidase and disease: prospects for therapy with reversible inhibitiors. Academic Press, London
50.
Trembath P.W., Turner P. (1979) Effect of a single oral dose of phenelzine on the tyramine pressor response and ocular responses in man. J Pharm Pharmacol31: 59-60
51.
Van Slyke L., Hart B. ( 1903) The relation of carbon dioxide to proteolysis in the ripening of cheddar cheese. Am Chem J30: 1-24
52.
Warrington S., Turner P., St John-Smith P., McClelland G. (1988a) Effects of single oral doses of moclobemide on the threshold of cardiovascular response to oral and intravenous tyramine . J Psychopharmacol2: meeting abstracts
53.
Warrington S., Mant T., Turner P., Morrison P., Haywood G., Glover V., Littlewood J., Sandler M., St John-Smith P., McClelland G. (1988b) Effects of repeated administration of phenelzine, selegiline, moclobemide and placebo, on the threshold of cardiovascular response to oral tyramine, and platelet MAO activity. J Psychopharmacol2: meeting abstracts
54.
Warrington S., Turner P., Glover V., Sandler M., St John-Smith P., Williams P., McClelland G. (1988c) Tolerance, pharmacokinetics and biochemical effects of single oral doses of moclobemide in normal volunteers. J Psychopharmacol2 : meeting abstracts
55.
White K., Simpson G.M. (1981) Combined MAOI tricyclic antidepressant treatment: a re-evaluation. J Clin Psychopharmacol1: 264-279
56.
Wijnands S., Chang P.C., Blauw G.J., van der Krogt J., Gieschke R., Schoerlin M.P., van Brummelen P. (1989) Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol3: 36-44
